What's Inside: 

Across recent approvals, nearly half of new therapies have underperformed their first-year forecasts, and two-thirds have fallen short of pre-launch expectations. For most, early underperformance sets a trajectory that is difficult to reverse. The first months after launch often determine whether a therapy gains traction or loses momentum.

That reality is especially true for infused and physician-administered products, where access depends on precise coordination across payers, providers, and sites of care. Temporary billing codes, payer configuration delays, and uneven site readiness can all slow adoption and stall patients before treatment begins.

The following guide explores how manufacturers can navigate this critical launch window. The guide outlines strategies to confirm payer readiness, prepare sites for billing and reimbursement changes, and maintain visibility from prescription to infusion—helping ensure operational alignment translates into timely patient access and a strong market start.

Download Now: